DK1240326T3 - Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor - Google Patents
Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptorInfo
- Publication number
- DK1240326T3 DK1240326T3 DK00989877T DK00989877T DK1240326T3 DK 1240326 T3 DK1240326 T3 DK 1240326T3 DK 00989877 T DK00989877 T DK 00989877T DK 00989877 T DK00989877 T DK 00989877T DK 1240326 T3 DK1240326 T3 DK 1240326T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor
- antibodies
- identify
- killer cells
- involved
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44051499A | 1999-11-15 | 1999-11-15 | |
| CA2288307A CA2288307C (en) | 1999-11-15 | 1999-11-15 | Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |
| PCT/EP2000/011697 WO2001036630A2 (en) | 1999-11-15 | 2000-11-15 | Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1240326T3 true DK1240326T3 (da) | 2009-06-02 |
Family
ID=25681295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00989877T DK1240326T3 (da) | 1999-11-15 | 2000-11-15 | Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1240326B1 (https=) |
| JP (1) | JP4776845B2 (https=) |
| AT (1) | ATE423848T1 (https=) |
| AU (1) | AU783899B2 (https=) |
| DE (1) | DE60041655D1 (https=) |
| DK (1) | DK1240326T3 (https=) |
| ES (1) | ES2321687T3 (https=) |
| WO (1) | WO2001036630A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10261223A1 (de) * | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
| WO2004056392A1 (en) * | 2002-12-23 | 2004-07-08 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same |
| EP1445614A1 (en) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A method for the in vitro assessment of the progression status of an HIV virus in an invidual |
| US7803376B2 (en) | 2003-07-24 | 2010-09-28 | Innate Pharma S.A. | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| WO2005105848A1 (en) * | 2004-04-30 | 2005-11-10 | Innate Pharma | Compositions and methods for enhancing nk cell activity |
| WO2006009731A1 (en) * | 2004-06-18 | 2006-01-26 | Genentech, Inc. | Methods of using apo2l receptor agonists and nk cell activators |
| ATE548389T1 (de) | 2004-08-03 | 2012-03-15 | Innate Pharma | Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor |
| EP1626059A1 (en) * | 2004-08-09 | 2006-02-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| AU2005321017B2 (en) | 2004-12-28 | 2011-02-24 | Innate Pharma S.A. | Monoclonal antibodies against NKG2A |
| AU2006301163B2 (en) | 2005-10-14 | 2012-02-23 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| KR101662622B1 (ko) * | 2007-10-04 | 2016-10-05 | 지모제넥틱스, 인코포레이티드 | B7 패밀리 구성원 zB7H6 및 관련된 조성물 및 방법 |
| AU2016299166B2 (en) * | 2015-07-24 | 2022-03-31 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| AU2018371114A1 (en) | 2017-11-21 | 2020-05-07 | Innate Pharma | Multispecific antigen binding proteins |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス,インコーポレーテッド | T細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| EP4448095A1 (en) | 2021-12-14 | 2024-10-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
| JP7821427B2 (ja) * | 2022-01-27 | 2026-02-27 | 学校法人 東洋大学 | ナチュラルキラー細胞活性の測定方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09502089A (ja) * | 1993-08-27 | 1997-03-04 | ダナ−ファーバー キャンサー インスティチュート インコーポレイテッド | ナチュラルキラー細胞特異性抗原およびこの抗原を識別する抗体 |
| ZA9810133B (en) * | 1997-11-07 | 1999-05-17 | Biogen Inc | BMOG a novel protein member of the myelin-oligodendrocyte glycoprotein family and its use for ummonomodulatory purposes |
| US7396681B1 (en) * | 1998-03-27 | 2008-07-08 | Gabriele Multhoff | Application of Hsp70 proteins |
-
2000
- 2000-11-15 AT AT00989877T patent/ATE423848T1/de active
- 2000-11-15 AU AU26677/01A patent/AU783899B2/en not_active Ceased
- 2000-11-15 ES ES00989877T patent/ES2321687T3/es not_active Expired - Lifetime
- 2000-11-15 DK DK00989877T patent/DK1240326T3/da active
- 2000-11-15 EP EP00989877A patent/EP1240326B1/en not_active Expired - Lifetime
- 2000-11-15 WO PCT/EP2000/011697 patent/WO2001036630A2/en not_active Ceased
- 2000-11-15 DE DE60041655T patent/DE60041655D1/de not_active Expired - Lifetime
- 2000-11-15 JP JP2001538509A patent/JP4776845B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001036630A9 (en) | 2002-09-19 |
| JP2003523735A (ja) | 2003-08-12 |
| EP1240326A2 (en) | 2002-09-18 |
| ATE423848T1 (de) | 2009-03-15 |
| WO2001036630A2 (en) | 2001-05-25 |
| AU783899B2 (en) | 2005-12-22 |
| JP4776845B2 (ja) | 2011-09-21 |
| ES2321687T3 (es) | 2009-06-10 |
| DE60041655D1 (de) | 2009-04-09 |
| EP1240326B1 (en) | 2009-02-25 |
| AU2667701A (en) | 2001-05-30 |
| WO2001036630A3 (en) | 2001-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1240326T3 (da) | Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor | |
| BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| AR029605A1 (es) | DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS | |
| DK1673397T3 (da) | Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer | |
| DE60234616D1 (de) | Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren | |
| ECSP034772A (es) | Antagonistas de mch y su uso en el tratamiento de obesidad | |
| BRPI0409133A (pt) | formulações farmacêuticas contendo metilnaltrexona | |
| HRP20020787B1 (hr) | Postupak liječenja upotrebom kompleksa ligand-imunogen | |
| IS6750A (is) | Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka | |
| DK0817847T4 (da) | IL-17-receptor | |
| UY26482A1 (es) | Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales | |
| EE05287B1 (et) | Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
| ES2246567T3 (es) | Composiciones para receptores inhibidores de celulas t y usos de las mismas. | |
| BRPI0510170B8 (pt) | composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto | |
| BR9807848B1 (pt) | Composto de arilsulfonamidas e análogos, bem como composição farmacêutica e uso dos mesmos. | |
| BRPI0311189B8 (pt) | composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso | |
| BRPI0413676A (pt) | composto, e, composição farmacêutica | |
| IL164464A0 (en) | Antagonists to mcp proteins, their preparation, pharmaceutical composition containing them, and their use | |
| EA200601759A1 (ru) | Композиции рамиприла | |
| EA200701172A1 (ru) | 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение | |
| NZ514696A (en) | IL-8 receptor antagonists | |
| MX9204613A (es) | Nitratos organicos, procedimientos para su preparacion y su uso en el tratamiento de enfermedades cardiovasculares | |
| ATE537249T1 (de) | Wiedergewinnung von gewebefunktion nach verabreichung von b-zellen an verletztes gewebe | |
| ATE384066T1 (de) | Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren | |
| MY143477A (en) | Il-8 receptor antagonists |